216 related articles for article (PubMed ID: 8837861)
1. Tyrosine and phenylalanine restriction sensitizes adriamycin-resistant P388 leukemia cells to adriamycin.
Elstad CA; Thrall BD; Raha G; Meadows GG
Nutr Cancer; 1996; 25(1):47-60. PubMed ID: 8837861
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic stability of B16-BL6 melanoma exposed to low levels of tyrosine and phenylalanine.
Elstad CA; Meadows GG
Anticancer Res; 1990; 10(5A):1313-8. PubMed ID: 2241108
[TBL] [Abstract][Full Text] [Related]
3. Modulation of B16-BL6 murine melanoma metastatic phenotype by tyrosine and phenylalanine restriction in the absence of host selection pressures.
Elstad CA; Meadows GG
Anticancer Res; 1993; 13(2):523-8. PubMed ID: 8517667
[TBL] [Abstract][Full Text] [Related]
4. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Goldenberg GJ; Wang H; Blair GW
Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
[TBL] [Abstract][Full Text] [Related]
5. Influence of tyrosine and phenylalanine limitation of cytotoxicity of chimeric TGF-alpha toxins on B16BL6 murine melanoma in vitro.
Fu YM; Li YQ; Meadows GG
Nutr Cancer; 1998; 31(1):1-7. PubMed ID: 9682242
[TBL] [Abstract][Full Text] [Related]
6. Intracellular adriamycin levels and cytotoxicity in adriamycin-sensitive and adriamycin-resistant P388 mouse leukemia cells.
Ganapathi R; Reiter W; Krishan A
J Natl Cancer Inst; 1982 Jun; 68(6):1027-32. PubMed ID: 6953267
[TBL] [Abstract][Full Text] [Related]
7. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
[TBL] [Abstract][Full Text] [Related]
8. Modulation of in vitro chemosensitivity by extracellular Ca++ in adriamycin sensitive and resistant P388 leukemic cells.
Adwankar MK; Chitnis MP
Neoplasma; 1990; 37(1):31-6. PubMed ID: 2320178
[TBL] [Abstract][Full Text] [Related]
9. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
Fichtner I; Stein U; Hoffmann J; Winterfeld G; Pfeil D; Hentschel M
Anticancer Res; 1994; 14(5A):1995-2003. PubMed ID: 7847840
[TBL] [Abstract][Full Text] [Related]
10. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of acquired resistance to methotrexate in P388 murine leukemia cells and in their doxorubicin-resistant subline.
Ramu N; Ramu A; Cole DE; Balis FM; Poplack DG; Pollard HB
Isr J Med Sci; 1988; 24(9-10):477-82. PubMed ID: 2974448
[TBL] [Abstract][Full Text] [Related]
12. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
13. Effects of Dex-Verapamil on Doxorubicin cytotoxicity in P388 murine leukemia cells.
Noviello E; Allievi E; Russo P; Parodi S
Anticancer Drug Des; 1997 Jun; 12(4):261-76. PubMed ID: 9199659
[TBL] [Abstract][Full Text] [Related]
14. [In vitro evaluation of the chemosensitivity of an experimental murine leukemia rendered resistant in vivo to adriamycin].
Lepri E; Menconi E; Barzi AM
Boll Soc Ital Biol Sper; 1984 Jul; 60(7):1369-75. PubMed ID: 6477749
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine.
Ganapathi R; Grabowski D
Cancer Res; 1983 Aug; 43(8):3696-9. PubMed ID: 6861140
[TBL] [Abstract][Full Text] [Related]
16. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.
Johnson RK; Chitnis MP; Embrey WM; Gregory EB
Cancer Treat Rep; 1978 Oct; 62(10):1535-47. PubMed ID: 709555
[TBL] [Abstract][Full Text] [Related]
17. Differential effect of collaterally sensitive antimetabolites on P388 murine leukemia sensitive and resistant to adriamycin in vitro.
Satyamoorthy K; Deshpande SS; Chitnis MP
Neoplasma; 1989; 36(6):673-83. PubMed ID: 2515459
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
Gautam SC; Chikkala NF; Lewis I; Grabowski DR; Finke JH; Ganapathi R
Anticancer Res; 1992; 12(3):921-5. PubMed ID: 1622150
[TBL] [Abstract][Full Text] [Related]
19. In vitro anti-multidrug resistance activities of acyclic and cyclic disulfonamides in murine leukemia cells.
Wakusawa S; Sawanishi H; Hayashi H
Anticancer Res; 1998; 18(4C):2961-5. PubMed ID: 9713492
[TBL] [Abstract][Full Text] [Related]
20. Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative.
De Jong G; Gelmon K; Bally M; Goldie J; Mayer L
Anticancer Res; 1995; 15(3):911-6. PubMed ID: 7645981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
